Athira Pharma (NASDAQ:ATHA) is presenting new data supporting its pipeline of small molecule therapeutic candidates designed to enhance the HGF/MET neurotrophic system at the Alzheimer’s Association International Conference in the Netherlands.
“These findings underscore the potential clinical utility of biomarkers of neurodegeneration and neuroinflammation in Alzheimer’s disease, and help elucidate the neuroprotective mechanisms of this promising product candidate,” ATH-1105, Hans. Moebius, M.D., Ph.D., CMO of Athira Pharma, said in a statement.
Kevin Church, Ph.D., CSO of Athira, said the company is encouraged by the growing body of preclinical research supporting ATH-1105, which shows that the molecule is protective against several pathologies common to ALS and FTD animal models.
“The consistency and breadth of these effects in reducing markers of inflammation, neurodegeneration, and TPD-43 protein pathology continue to support the broad therapeutic potential and continued advancement of ATH-1105,” he added.
